Skip to main content
OpenTrials
Completed

NCT Number: NCT02329899

Standardisation of Investigations of Mild Bleeding Disorders

Observational study aimed at evaluating the clinical impact of a standardised diagnostic procedure for the investigation of patients with suspected mild bleeding disorder (MBD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Haemostasis unit, University Hospitals of Geneva

Geneva, 1205, Switzerland

About this study

The working hypothesis of this prospective diagnostic study is that a standardised procedure in investigating patients with suspected MBD will lead to a better discrimination between patients with and without MBD and a more precise characterisation of MBD.

The primary objective of this diagnostic study is to evaluate the efficiency of a standardised procedure of MBD in children and adults referred to their respective outpatient clinics for bleeding symptoms. The following endpoints will be evaluated:

  • The relative number of precise diagnosis (according to recognised classification of haemostatic disorders) in each clinical probability category;
  • The number of biological tests performed per patient in each clinical probability category;
  • The relative number of patients with no specialised investigations in the low risk group.

The secondary objective is to evaluate the bleeding events during a one-year follow-up. Follow-up will be performed with a phone call one year after the last consultation of the patient. The definition of a bleeding event will be any bleeding that promotes any specific medical attention (consultation, hospitalisation, transfusion, re-intervention in case of surgery). The detailed clinical history regarding each event will be collected. Bleeding events will be correlated to the clinical probability assessed at inclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients aged more than two years-old referred by their physician (gynaecologist, paediatrician, general practitioner, surgeon, etc.) for investigations of a possible bleeding tendency will be included in this study. This prospective study will include consecutive patients attending the four outpatient clinics (Division of Angiology and Haemostasis and Paediatric Onco-Haematology Unit, University Hospitals of Geneva).

Exclusion criteria

  • Pregnant women will be excluded because of modifications of the known modifications of the haemostasis system during pregnancy. Adult patients without discernment capacity will be excluded.

Treatment and study plan

Second step of investigations

Other

Second step according to results of the first step:

  • exploration of coagulation factors;
  • factor XIII and fibrinolysis investigations;
  • investigation of platelet function;
  • investigation of thrombocytopenia.

Primary outcomes

  1. Relative number of precise diagnosis

    Time frame: after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)

    Diagnosis are going to be evaluated according to recognized classification of haemostatic disorders

  2. Number of biological tests performed per patient

    Time frame: after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)

  3. Relative number of patients with no specialised investigations in the low risk group

    Time frame: after the completion of the standardized diagnostic procedure (on average 1 week after enrollment in this low risk group)

Secondary outcomes

  1. Evaluation of bleeding events

    Time frame: After one year follow-up

    Phone call

Sponsors and collaborators

Lead sponsor

University Hospital, Geneva

Other

Registry information

Acronym: MBD

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Jan 1, 2015
Registry last updated
Nov 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.